Geneus Tech Inc. is a biotechnology startup based in the Bay Area. It is a subsidiary of a Chinese parent company and focuses on developing 4th generation gene sequencing solutions, utilizing nanopore-based technology. The company's core technology platform involves detecting and processing characteristic current signals from nanopore biosensors and nucleic acid bases, enabling high-throughput sequencing at the single-molecule level through an integrated chip system.
The company recently achieved a major milestone by launching the alpha version of its first-generation product, signaling significant progress in its R&D efforts. This development has attracted Series B investments from GF Xinde and Dean Diagnostics in March 2, 2023, reflecting the industry's confidence in the company's potential and the technology's impact on the gene sequencing field.
Geneus Tech Inc.'s innovative approach aims to revolutionize gene sequencing by offering higher data quality, lower costs, and enhanced convenience, ultimately contributing to the advancement of precision and personalized medicine. The company is also actively recruiting top talent in the Bay Area, offering competitive salaries, benefits, equity, and a promising career path within a dynamic work environment.
